Clinical Ink, a Winston-Salem, NC and Philadelphia, PA-based provider of eSource solutions for clinical trials, merged with CentrosHealth, a Boston, MA-based provider of configurable mobile apps for clinical trial patient engagement and electronic patient reported outcomes (ePRO) founded by MPM Capital.
The combination of Clinical Ink and CentrosHealth aims to create a clinical trial technology platform with the ability to conduct paperless clinical trials with purpose-built solutions for pharma companies, research sites, and patients.
The company also announced that MPM Capital and F2 Ventures joined FCA Venture Partners and other existing investors to provide additional growth capital for Clinical Ink to expand operational capabilities and further development of its paperless clinical trial platform. As a result of this transaction, representatives from MPM Capital and F2 Ventures will join the existing board of directors of Clinical Ink.
Led by Ed Seguine, CEO, Clinical Ink additionally entered into a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to drive industry-wide adoption of fully electronic clinical trials.